Refine
Year of publication
Has Fulltext
- yes (55)
Is part of the Bibliography
- no (55)
Keywords
- Mammakarzinom (12)
- breast cancer (12)
- Behandlung (8)
- Metastasen (8)
- CDK4/6 (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- treatment (6)
- metastases (5)
- Risiko (4)
- risk (4)
- trials (4)
- metastatic (3)
- Alpelisib (2)
- Atezolizumab (2)
- Contact Ion Pairs (2)
- Diagnostik (2)
- ESR/ENDOR Spectra (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Früherkennung (2)
- Katherine (2)
- Lokalrezidiv (2)
- Nachsorge (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Richtlinie (2)
- Supportivtherapie (2)
- T‑DM1 (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- alpelisib (2)
- atezolizumab (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- guideline (2)
- local recurrence (2)
- neoadjuvant therapy (2)
- neoadjuvante Therapie (2)
- predictive factors (2)
- prognostic factors (2)
- screening (2)
- studies (2)
- supportive therapy (2)
- treatment/therapy (2)
- AML (1)
- APRI (1)
- Acute myeloid leukemia (1)
- Advanced breast cancer (1)
- All-trans retinoic acid (1)
- Antihormone therapy (1)
- Bröckeltonstein (1)
- CDI (1)
- CVID (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Cleanliness level (1)
- Clinical presentation (1)
- Colon capsule endoscopy (1)
- Colorectal cancer (1)
- Complementation rate (1)
- Cyclic Voltammetry (1)
- Dinosaur habitats (1)
- EMT (1)
- ENDOR and Triple Spectra (1)
- ESR (1)
- Entomology (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- FIB-4 (1)
- Fibrotest (1)
- Genomic instability (1)
- German PID-NET registry (1)
- HBV (1)
- HCV (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- HIV (1)
- Heavy Ion Experiments (1)
- Hepatotoxicity (1)
- Heregulin (1)
- High-throughput screening (1)
- Hyperammonemic encephalopathy (1)
- Hypertension (1)
- IgG substitution therapy (1)
- Incomplete colonoscopy (1)
- Induction chemotherapy (1)
- Inverse kinematics (1)
- Isoscalar giant resonances (1)
- JAWSTAT pathway (1)
- Jurassic sequences (1)
- Kidney transplantation (1)
- Liver enzymes (1)
- Low volume prep (1)
- MM-121 (1)
- Metastatic (1)
- Molecular medicine (1)
- Molecular modelling (1)
- Moviprep (1)
- Natural Quinones (1)
- Neonatal urea cycle disorders (1)
- Nucleophosmin-1 (1)
- PID prevalence (1)
- Paleo-Vertisols (1)
- Pathology Section (1)
- Phospho-soda (1)
- Phylogenomics (1)
- PillCamColon2 (1)
- Polyps (1)
- Population genetics (1)
- RNASolution-state NMR (1)
- Radical Anions (1)
- Radical Contact Ion Pairs (1)
- Reduction of 1-Sila-2,5-diazacyclopentane-3,4-dithione and of Tetrakis(isopropylthio)-p-benzoquinone (1)
- Renal function (1)
- SLUG (1)
- STAT3 (1)
- Seribantumab (1)
- Storage ring (1)
- T-DM1 (1)
- TGF-β (1)
- Target validation (1)
- Tetraketone Radical Anion (1)
- Transient elastography (1)
- Wiehengebirge (1)
- acoustic radiation force impulse imaging (1)
- advanced breast cancer (1)
- antihormone therapy (1)
- axions (1)
- cART (1)
- cGMP (1)
- cell proliferation (1)
- chemotherapy (1)
- co-infection (1)
- cyclosporine (1)
- dark matter experiments (1)
- efficacy (1)
- everolimus (1)
- fibrotest (1)
- kidney transplantation (1)
- lapatinib (1)
- metastasis (1)
- monocrotaline (1)
- mycophenolate mofetil [MMF] (1)
- mycophenolic acid (1)
- nitric oxide (1)
- non-invasive fibrosis assessment (1)
- pericytes (1)
- pertuzumab (1)
- point shear wave elastography (1)
- primary immunodeficiency (PID) (1)
- pulmonary hypertension (1)
- randomized (1)
- registry for primary immunodeficiency (1)
- remodelling (1)
- renal function (1)
- solar physics (1)
- tacrolimus (1)
- transient elastography (1)
- trastuzumab (1)
- white and brown dwarfs (1)
- xenograft (1)
Institute
- Medizin (32)
- Physik (9)
- Biochemie und Chemie (8)
- Frankfurt Institute for Advanced Studies (FIAS) (7)
- Informatik (4)
- Informatik und Mathematik (2)
- Biowissenschaften (1)
- ELEMENTS (1)
- Extern (1)
- Exzellenzcluster Makromolekulare Komplexe (1)
A new technique developed for measuring nuclear reactions at low momentum transfer with stored beams in inverse kinematics was successfully used to study isoscalar giant resonances. The experiment was carried out at the experimental heavy-ion storage ring (ESR) at the GSI facility using a stored 58Ni beam at 100 MeV/u and an internal helium gas-jet target. In these measurements, inelastically scattered α-recoils at very forward center-of-mass angles (θcm ≤ 1.5°) were detected with a dedicated setup, including ultra-high vacuum compatible detectors. Experimental results indicate a dominant contribution of the isoscalar giant monopole resonance at this very forward angular range. It was found that the monopole contribution exhausts 79+12−11% of the energy-weighted sum rule (EWSR), which agrees with measurements performed in normal kinematics. This opens up the opportunity to investigate the giant resonances in a large domain of unstable and exotic nuclei in the near future. It is a fundamental milestone towards new nuclear reaction studies with stored ion beams.
The structurally different radical anions M⊖ of peralkylated 1-sila-2,5-diazacyclopentane-3,4-dithione and of tetrakis(isopropylthio)-p-benzoquinone are generated by reduction with potassium/2.2.2-cryptand under aprotic conditions in THF solution. On addition of Li⊕B(C6H5)4⊖, both form hitherto elusive sulfur-containing contact ion pairs, which are characterized by their ESR/ENDOR spectra.
Background and Aims: In patients with advanced liver cirrhosis due to chronic hepatitis C virus (HCV) infection antiviral therapy with peginterferon and ribavirin is feasible in selected cases only due to potentially life-threatening side effects. However, predictive factors associated with hepatic decompensation during antiviral therapy are poorly defined.
Methods: In a retrospective cohort study, 68 patients with HCV-associated liver cirrhosis (mean MELD score 9.18±2.72) were treated with peginterferon and ribavirin. Clinical events indicating hepatic decompensation (onset of ascites, hepatic encephalopathy, upper gastrointestinal bleeding, hospitalization) as well as laboratory data were recorded at baseline and during a follow up period of 72 weeks after initiation of antiviral therapy. To monitor long term sequelae of end stage liver disease an extended follow up for HCC development, transplantation and death was applied (240weeks, ±SD 136weeks).
Results: Eighteen patients (26.5%) achieved a sustained virologic response. During the observational period a hepatic decompensation was observed in 36.8%. Patients with hepatic decompensation had higher MELD scores (10.84 vs. 8.23, p<0.001) and higher mean bilirubin levels (26.74 vs. 14.63 µmol/l, p<0.001), as well as lower serum albumin levels (38.2 vs. 41.1 g/l, p = 0.015), mean platelets (102.64 vs. 138.95/nl, p = 0.014) and mean leukocytes (4.02 vs. 5.68/nl, p = 0.002) at baseline as compared to those without decompensation. In the multivariate analysis the MELD score remained independently associated with hepatic decompensation (OR 1.56, 1.18–2.07; p = 0.002). When the patients were grouped according to their baseline MELD scores, hepatic decompensation occurred in 22%, 59%, and 83% of patients with MELD scores of 6–9, 10–13, and >14, respectively. Baseline MELD score was significantly associated with the risk for transplantation/death (p<0.001).
Conclusions: Our data suggest that the baseline MELD score predicts the risk of hepatic decompensation during antiviral therapy and thus contributes to decision making when antiviral therapy is discussed in HCV patients with advanced liver cirrhosis.
Background: Accurate assessment of hepatic fibrosis in patients with chronic HBeAg-negative Hepatitis B is of crucial importance not only to predict the long-term clinical course, but also to evaluate antiviral therapy indication. The aim of this study was to prospectively assess the utility of point shear wave elastography (pSWE) for longitudinal non-invasive fibrosis assessment in a large cohort of untreated patients with chronic HBeAg-negative hepatitis B virus (HBV) infection.
Methods: 407 consecutive patients with HBeAg-negative HBV infection who underwent pSWE, transient elastography (TE) as well as laboratory fibrosis markers, including fibrosis index based on four factors (FIB-4), aspartate to platelet ratio index (APRI) and FibroTest, on the same day were prospectively followed up for six years. Patients were classified into one of the three groups: inactive carriers (IC; HBV-DNA <2000 IU/mL and ALT <40 U/L); grey zone group 1 (GZ-1; HBV DNA <2000 IU/mL and ALT >40 U/L); grey zone group 2 (GZ-2; HBV-DNA >2000 IU/mL and ALT <40 U/L).
Results: pSWE results were significantly correlated with TE (r = 0.29, p < 0.001) and APRI (r = 0.17; p = 0.005). Median pSWE values did not differ between IC, GZ-1 and GZ-2 patients (p = 0.82, p = 0.17, p = 0.34). During six years of follow-up, median pSWE and TE values did not differ significantly over time (TE: p = 0.27; pSWE: p = 0.05).
Conclusion: Our data indicate that pSWE could be useful for non-invasive fibrosis assessment and follow-up in patients with HBeAg-negative chronic HBV infection.
Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-exome and genome sequencing within a precision oncology program, that advanced chordomas (n = 11) may be characterized by genomic patterns indicative of defective homologous recombination (HR) DNA repair and alterations affecting HR-related genes, including, for example, deletions and pathogenic germline variants of BRCA2, NBN, and CHEK2. A mutational signature associated with HR deficiency was significantly enriched in 72.7% of samples and co-occurred with genomic instability. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. These findings uncover a therapeutic opportunity in chordoma that warrants further exploration, and provide insight into the mechanisms underlying PARP inhibitor resistance.